5.4K views | How can an RNA be used to treat myotonic dystrophy? ARTHEx biotech is focused on the development of the next generation of RNA therapies for genetic diseases. Our first product in the pipeline is a first-in-class treatment against myotonic dystrophy type 1, an orphan and rare disease. This therapy is based on an antisense oligonucleotide that inhibits the action of microRNAs (also known as antimiR). Learn more now: | Sci Ani | Facebook

Multiple myeloma is a blood cancer that most often occurs in people over age 45. It's the second-most common blood cancer and the most common blood cancer in Black people. Right now, there is no cure for the disease. But as Dr. Joselle Cook, a Mayo Clinic hematologist, explains, recent advances in treatment are helping people live longer. Learn more: https://mayocl.in/48QiIAz | Mayo Clinic